- Home
- UROY vs SGHT Comparison
UROY vs SGHT Comparison
Compare UROY & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- SGHT
- Stock Information
- Founded
- UROY 2017
- SGHT 2011
- Country
- UROY Canada
- SGHT United States
- Employees
- UROY N/A
- SGHT N/A
- Industry
- UROY
- SGHT Medical Specialities
- Sector
- UROY
- SGHT Health Care
- Exchange
- UROY Nasdaq
- SGHT Nasdaq
- Market Cap
- UROY 294.0M
- SGHT 304.4M
- IPO Year
- UROY N/A
- SGHT 2021
- Fundamental
- Price
- UROY $2.13
- SGHT $3.55
- Analyst Decision
- UROY Strong Buy
- SGHT Buy
- Analyst Count
- UROY 2
- SGHT 7
- Target Price
- UROY $5.60
- SGHT $6.27
- AVG Volume (30 Days)
- UROY 2.4M
- SGHT 218.9K
- Earning Date
- UROY 12-12-2024
- SGHT 11-07-2024
- Dividend Yield
- UROY N/A
- SGHT N/A
- EPS Growth
- UROY 256.61
- SGHT N/A
- EPS
- UROY 0.03
- SGHT N/A
- Revenue
- UROY $27,478,292.00
- SGHT $79,543,000.00
- Revenue This Year
- UROY N/A
- SGHT $2.13
- Revenue Next Year
- UROY $72.53
- SGHT $7.99
- P/E Ratio
- UROY $83.69
- SGHT N/A
- Revenue Growth
- UROY 31.26
- SGHT N/A
- 52 Week Low
- UROY $1.86
- SGHT $3.30
- 52 Week High
- UROY $3.76
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- UROY 33.80
- SGHT 39.11
- Support Level
- UROY $2.06
- SGHT $3.30
- Resistance Level
- UROY $2.70
- SGHT $3.64
- Average True Range (ATR)
- UROY 0.14
- SGHT 0.20
- MACD
- UROY -0.02
- SGHT 0.02
- Stochastic Oscillator
- UROY 10.94
- SGHT 30.67
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.